Gastrointestinal Cancers News

First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC

First-Line Atezolizumab Plus Bevacizumab Receives Breakthrough Therapy Designation for HCC

Twenty-three systemic therapy-naive patients with advanced hepatocellular carcinoma received atezolizumab plus bevacizumab every 3 weeks.

FDA Approves Nivolumab Plus Ipilimumab for MSI-H/dMMR Metastatic Colorectal Cancer

FDA Approves Nivolumab Plus Ipilimumab for MSI-H/dMMR Metastatic Colorectal Cancer

The FDA based its approval on evidence from the ongoing, non-randomized CheckMate-142 phase 2 study, for which researchers treated 119 patients with nivolumab plus ipilimumab.

Trifluridine/Tipiracil Improves OS, PFS in Metastatic Gastric Cancer

Trifluridine/Tipiracil Improves OS, PFS in Metastatic Gastric Cancer

Trifluridine plus tipiracil may be an effective treatment option for patients with heavily pretreated metastatic gastric cancer, according to presenters at ESMO 2018.

Real-World Study Reports PFS and OS in Metastatic CRC

Real-World Study Reports PFS and OS in Metastatic CRC

A Merck-funded study examines survival data on patients with metastatic colorectal cancer; results were presented during ESMO 2018.

Benefit of Ramucirumab in Relapsed Hepatocellular Carcinoma Confirmed in Pooled Analysis

Benefit of Ramucirumab in Relapsed Hepatocellular Carcinoma Confirmed in Pooled Analysis

Ramucirumab prolonged progression-free survival (PFS) and overall survival (OS) in patients with relapsed/refractory hepatocellular carcinoma (HCC).

Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer

Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer

A recent trial evaluated the safety and efficacy of a DC vaccine combined with salvage chemotherapy.

Autophagy-Related Proteins May Be Prognostic Factors for CRC Survival With Chemotherapy

Autophagy-Related Proteins May Be Prognostic Factors for CRC Survival With Chemotherapy

Researchers sought to determine if autophagy-related proteins are associated with survival among patients with CRC.

Real-World Regorafenib Outcomes Mirror Clinical Trial Results in Metastatic Colorectal Cancer

Real-World Regorafenib Outcomes Mirror Clinical Trial Results in Metastatic Colorectal Cancer

CORRECT and CONCUR trials demonstrated an improvement in OS for patients receiving regorafenib compared with placebo.

Cetuximab/Irinotecan Rechallenge Active in Resistant Metastatic Colorectal Cancer

Cetuximab/Irinotecan Rechallenge Active in Resistant Metastatic Colorectal Cancer

The CRICKET trial is evaluating the third-line retreatment of patients with mCRC with cetixumab plus irinotecan.

No Benefit With Addition of EGFR Inhibitor to Chemotherapy in Esophageal Cancer

No Benefit With Addition of EGFR Inhibitor to Chemotherapy in Esophageal Cancer

The addition of an EGFR inhibitor to a chemotherapy regimen did not improve outcomes when it came to cancers of the esophagus.

Risk of Brain Metastasis in Colorectal Cancer Dependent on Tumor Location and Other Metastatic Sites

Risk of Brain Metastasis in Colorectal Cancer Dependent on Tumor Location and Other Metastatic Sites

In patients with colorectal cancer, rectal tumors and lung metastasis appeared to be linked to an elevated risk for brain cancer.

Capecitabine-Activating Enzyme Levels Prognostic for Metastatic Gastric Cancer Outcomes

Capecitabine-Activating Enzyme Levels Prognostic for Metastatic Gastric Cancer Outcomes

XP-treated patients with metastatic gastric cancer who had tumors expressing UCK2 and OPRT above a specific threshold survived longer than patients with lower levels of these biomarkers.

Increasing the Mutant Allele Fraction Cutoff in NGS Improved Mutation Detection in mCRC

Increasing the Mutant Allele Fraction Cutoff in NGS Improved Mutation Detection in mCRC

Increasing the sensitivity cutoff from 5% to 1% in next-generation sequencing allowed for the identification of 28% more RAS/BRAF mutations.

Baseline Appetite Associated With Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma

Baseline Appetite Associated With Outcomes in Metastatic Pancreatic Ductal Adenocarcinoma

A study reported post-hoc subgroup analyses of the international phase 3 NAPOLI-1 trial.

Liquid Biopsy Test Accurately Detects RAS Mutations in Metastatic Colorectal Cancer

Liquid Biopsy Test Accurately Detects RAS Mutations in Metastatic Colorectal Cancer

The OncoBEAM RAS kit for circulating tumor DNA (ctDNA) analysis of patients with metastatic colorectal cancer (mCRC) demonstrated high positive and negative agreement of RAS mutations detected by tumor tissue analysis.

Better Quality of Life With Nab-Paclitaxel Added to Gemcitabine in Pancreatic Cancer

Better Quality of Life With Nab-Paclitaxel Added to Gemcitabine in Pancreatic Cancer

The combination of nab-paclitaxel plus gemcitabine improved quality of life scores and increased time to deterioration compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).

Adding Oxaliplatin to Capecitabine-Based Chemotherapy, Radiation May Not Improve Survival in Rectal Cancer

Adding Oxaliplatin to Capecitabine-Based Chemotherapy, Radiation May Not Improve Survival in Rectal Cancer

Researchers randomly assigned 1090 patients with advanced rectal adenocarcinoma to 5 weeks of preoperative capecitabine-based chemoradiation followed by 6 cycles of capecitabine alone or with oxaliplatin.

Nodal Response to Neoadjuvant Therapy Predictive of Survival in Esophageal Cancer

Nodal Response to Neoadjuvant Therapy Predictive of Survival in Esophageal Cancer

Findings on the predictive nature of nodal response to neoadjuvant therapy from the American Association for Thoracic Surgery 98th Annual Meeting.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs